Maravai LifeSciences (NASDAQ:MRVI) Reaches New 52-Week High – Here’s What Happened

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $6.61 and last traded at $6.4530, with a volume of 146820 shares. The stock had previously closed at $6.36.

Analysts Set New Price Targets

MRVI has been the topic of a number of recent analyst reports. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.50.

Maravai LifeSciences Stock Performance

The stock has a 50-day moving average price of $5.20 and a 200 day moving average price of $4.02. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.92 and a beta of 0.65.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The firm had revenue of $65.84 million for the quarter, compared to analysts’ expectations of $53.00 million. On average, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current year.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel directly owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its position in shares of Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock worth $20,595,000 after acquiring an additional 178,445 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Maravai LifeSciences by 1.7% in the fourth quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock valued at $20,148,000 after purchasing an additional 104,355 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Maravai LifeSciences by 0.9% in the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock valued at $12,069,000 after purchasing an additional 39,600 shares in the last quarter. Tejara Capital Ltd increased its stake in Maravai LifeSciences by 23.1% in the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Maravai LifeSciences by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after purchasing an additional 34,447 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.